– Applications for the 2024-2025 academic year will be accepted until May 13, 2024
– Scholarships will be awarded to up to 20 individuals living with Duchenne muscular dystrophy and up to five siblings of individuals living with Duchenne
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 29, 2024--
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year. Academic scholarships of up to $5,000 will be awarded to as many as 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne.
Applications will be accepted until Monday, May 13, 2024, at 11:59 p.m. PDT. Recipients will be notified prior to August 2024 and awards will be distributed directly to the school, college or university in time for fall 2024 enrollment. Students may learn more about the program and how to apply by visiting sarepta.com/route79.
“Sarepta is proud to announce the opening of Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year. In recognition of the magnitude a Duchenne muscular dystrophy diagnosis brings to the entire household, we continue to invite students who live with Duchenne or have a sibling who lives with Duchenne to apply as they pursue their educational goals for the year,” said Diane Berry, Ph.D., Sarepta’s Executive Vice President and Chief Global Policy & Advocacy Officer. “The Route 79 program embodies Sarepta's unwavering commitment to the Duchenne community and helps nurture brighter futures. Every year, we are profoundly moved by each applicant’s narrative and dedication to their educational pursuits. We are excited to learn about this year’s pool of applicants and look forward to supporting our growing community of Route 79 scholars.”
To apply for a scholarship through the Route 79 program, applicants must be accepted to or enrolled in an accredited college or university, or a trade, technical or vocational school located in the United States. Only applicants diagnosed with Duchenne or applicants who have a sibling diagnosed with Duchenne are eligible for the program. College seniors or college graduates accepted to or enrolled in graduate school are also eligible to apply. Previous recipients of Route 79 scholarships may apply for the 2024 Scholarship Program, however, applicants may only receive a Route 79 scholarship up to four times. No consideration is given to whether an applicant was previously, is currently, or expects to be in the future, undergoing treatment with a Sarepta product or investigational therapy. For additional applicant criteria, please visit www.sarepta.com/route79.
About Route 79, The Duchenne Scholarship Program
The Route 79 program is designed to help students living with Duchenne and siblings of individuals living with Duchenne pursue their post-secondary educational goals. Scholarship recipients are chosen by an independent committee of Duchenne community members based on an applicant’s community involvement, personal essay, and recommendation letter. The underlying cause of Duchenne is a mutation or error in the gene coding for dystrophin. Dystrophin is an essential protein that plays a pivotal role in muscle structure, function and preservation. The numerical significance of the scholarship’s name, Route 79, ties to the 79 exons of the dystrophin gene. For more information, visit sarepta.com/route79.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229172355/en/
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contacts:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Sierra Smith, 617-710-1385
sismith@sarepta.com
Source: Sarepta Therapeutics, Inc.
